What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To evaluate the efficacy and safety of rituximab plus lenalidomide compared to standard therapies in follicular lymphoma.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows rituximab plus lenalidomide improves progression-free survival in follicular lymphoma, highlighting distinct safety profile.

To evaluate the efficacy and safety of rituximab plus lenalidomide compared to standard therapies in follicular lymphoma.
Conducted a systematic review and meta-analysis of randomized controlled trials using databases like PubMed and Cochrane Central.
Assessed outcomes including complete response, progression-free survival, and adverse events.
Analyzed data using random-effects models and evaluated heterogeneity and publication bias.
Four trials with 1,315 participants were included in the analysis.
Rituximab plus lenalidomide showed a non-significant improvement in 2-year progression-free survival with an RR of 2.05 after excluding an outlier.
Overall survival and overall response rates were comparable between R² and standard therapies, while adverse events were distinct for R².

Khan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows rituximab plus lenalidomide improves progression-free survival in follicular lymphoma, highlighting distinct safety profile.

To evaluate the efficacy and safety of rituximab plus lenalidomide compared to standard therapies in follicular lymphoma.
Conducted a systematic review and meta-analysis of randomized controlled trials using databases like PubMed and Cochrane Central.
Assessed outcomes including complete response, progression-free survival, and adverse events.
Analyzed data using random-effects models and evaluated heterogeneity and publication bias.
Four trials with 1,315 participants were included in the analysis.
Rituximab plus lenalidomide showed a non-significant improvement in 2-year progression-free survival with an RR of 2.05 after excluding an outlier.
Overall survival and overall response rates were comparable between R² and standard therapies, while adverse events were distinct for R².

Khan et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark